Skip to main content

Table 1 Preoperative characteristics of 109 ER-positive/HER2-negative breast cancer patients who underwent neoadjuvant chemotherapy

From: Utility of 18F-FDG PET/CT for predicting pathologic complete response in hormone receptor-positive, HER2-negative breast cancer patients receiving neoadjuvant chemotherapy

  Number Percent
Median age, years (range) 47.0 (29–68)  
Menopausal status
 Pre 75 68.8
 post 34 31.2
Histology
 Ductal 103 94.5
 Lobular 3 2.8
 Metaplastic 2 1.8
 mucinous 1 0.9
Tumor size (cT)a
 1 8 7.3
 2 77 70.6
 3 18 16.5
 4 6 5.5
Lymph node involvement (cN)a
 0 8 7.3
 1 46 42.2
 2 45 41.3
 3 10 9.2
Clinical stage (cS)a
 2A 10 9.2
 2B 36 33.0
 3A 48 44.0
 3B 5 4.6
 3C 10 9.2
ER, Allred score
 0–2 8 7.3
 3–5 14 12.8
 6–8 87 79.8
PR, Allred score
 0–2 13 11.9
 3–5 20 18.3
 6–8 76 69.7
Ki67 index, %
  < 14 54 49.5
 14–100 55 50.5
Molecular subtypeb
 Luminal A-like 48 44.0
 luminal B-like 61 56.0
Regimens
 AC4T4c 103 94.5
 AC4 4 3.7
 TC4 2 1.8
Surgery
 BCS 36 33.0
 mastectomy 73 67.0
SUVmax on 18F-FDG PET/CT at diagnosis
 SUVmax at breast (pSUVmax), mean + SD 9.19 ± 6.34  
  <  9.55 66 60.6
  ≥ 9.55 43 39.4
SUVmax at axilla, mean + SD 6.14 ± 50.3  
 NDd 23 21.1
 x < 6.14 55 50.5
  ≥ 6.14 31 28.4
  1. Abbreviations: ER Estrogen receptor, PR Progesterone receptor, AC Anthracycline + cyclophosphamide, T Taxane, TC Docetaxel + cyclophosphamide, BCS Breast conserving surgery, PET Positron emission tomography, SUV Standard uptake value, ND Not detected
  2. aAJCC 8th edition
  3. bEstimated by the results of immunohistochemical staining for ER, PR, HER2, and Ki67
  4. cOne patient received fewer than the planned number of courses (6 out of 8 cycles) because of intolerance
  5. dIncludes 8 cN0 cases
\